Latest filing published 04 Feb 2026 for Akebia Therapeutics, Inc., €63k.
Nicholas Grund has filed trades across 2 companies (mainly through SEC (Form 4)), most often in AMAG Pharmaceuticals Inc. and Akebia Therapeutics, Inc. We count 14 filings; the first trade dates from 4 January 2016 and the latest from 2 February 2026.
Every open-market trade on record is a sale: 1 sale worth €63k. Other entries cover 13 share grants. 2026 to date brings no purchases and 1 sale.
The newest entry dates from 4 February 2026: an open-market sale of €63k, in Akebia Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations